0590 x 2 04/09 patent

DOCKET NO.: PANT-0301

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Peter E. Nielsen, et al.

Serial No.: 10/083,259

Group Art Unit: Not yet assigned

Filing Date: October 19, 2001

Examiner: Not yet assigned

For: MODIFIED PEPTIDE NUCLEIC ACID (PNA) MOLECULES

DATE OF DEPOSIT: 4 APRIL 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

WASHINGTON, DC 20231.

TYPED NAME: Paul K. Legaard REGISTRATION NO.: 38,534

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

\*\*

Ť

28.5

ź

1

	In accordance with §1.129(a), this Information Disclosure Statement is						
	filed in connection with $\square$ the first or $\square$ second After Final Submission,						
	therefore:						
	☐ Certification in Accordance with §1.97(e) is attached; or						
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.						
	In accordance with §1.97(c), this Information Disclosure Statement is being filed						
	after the period set forth in §1.97(b) above but before the mailing date of either						
	a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an						
	action that otherwise closes prosecution in the application, therefore:						
	☐ Certification in Accordance with §1.97(e) is attached; or						
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.						
	In accordance with §1.97(d), this Information Disclosure Statement is being filed						
	after the mailing date of either a Final Action under §1.113 or a Notice of						
	Allowance under §1.311 but before, or simultaneously with, the payment of the						
	Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and						
	the submission fee of \$180.00 as set forth in §1.17(p).						
	Copies of each of the references listed on the attached Form PTO-1449 are						
	enclosed herewith.						
$\boxtimes$	Copies of references listed on the attached Form PTO-1449 are enclosed herewith						
	EXCEPT THAT:						
	In view of the voluminous nature of references AP, AW and BM, and the						
	likelihood that these references are available to the Examiner, copies are						
•	not enclosed herewith.						

÷ >

1.75

.

Ņ

- In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§120 have been made in the instant application:
- Copies of references AA-AO, AQ-AV, AX-BL and BN-CT listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/689,155, filed October 12, 2000.
  - ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: 4 APRIL 2002

100

Š

u,

Paul K. Legaard
Registration No. 38,534

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

Č 2001 WW

3

#### COPY OF PAPERS ORIGINALLY FILED

Sheet 1 of 7

15	·		Sheet 1 of /	
Form ]	PTO-1449 Modified	Docket No. PANT-0301	Serial No. 10/083,259	
C	Patent and Publications  Cited by Applicant veral sheets if necessary)	Applicant Peter E. Nielsen, et al.		
	epartment of Commerce and Trademark Office	Filing Date October 19, 2001	Group Not yet assigned	
OTHE	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
AA	Arthur, M., et al., "Glycopeptide resi 4(10), 401-407	stance in enterococci,'	' Trends Microbiol, <b>1996</b> ,	
AB	Baquero, F., "Pneumococcal resistan overview," Microb Drug Resist., 199	ce to β-lactam antibiot <b>5</b> , <i>1(2)</i> , 115-120	ics: a global geographic	
AC	Berge, S.M., et al., "Pharmaceutical	salts," J. Pharm. Scien	ces, <b>1977</b> , 66(1), 1-19	
AD	Bert, F., et al., "Comparitive distribution pseudomonas aeruginosa isolates from Antimicrob Chemother, 1996, 37, 80	itive distribution of resistance patterns and serotypes in a isolates from intensive care units and other wards," J. 1996, 37, 809		
AE	Broome-Smith, et al., "The nucleotic encoding penicillin-binding proteins 1985, 147, 437-446	ucleotide sequences of the ponA and ponB genes roteins 1A and 1B of Escherichia coli K12," FEBS,		
AF	Carmelli, Y., et al., "The association hospital-acquired vancomycin-resist 2461-2468	ne association between antecedent vancomycin treatment and omycin-resistant enterococci," Arch Intern. Med., 1999, 159,		
AG	Chambers, H.F., "Methicillin resista basis and clinical implications," Clin	nce in staphylococci: No. Microbiol. Rev., 199	Molecular and biochemical 7, 10(4), 781-791	
АН	CDR Weekly, Communicable Disea 9(8), 65-75	se Report, ISSN 1350-	.9357, February 19, <b>1999</b> ,	
AI	AI CDR Review, Communicable Disease Report, ISSN 1350-9349, November 10, 19 5(7), R173-R188			
AJ	Cookson, B.D., "Nosocomial antimicrobial resistance surveillance," <i>J. Hosp. Infec.</i> , <b>1999</b> , 43 (Supplement), S97-S103			
AK	AK Costerton, J.W., et al., "Bacterial biofilms in nature and disease," Ann Rev. Microbiol., 1987, 41, 435-464			
AL	Davis, J., et al., "Inactivation of anti Science, 1994, 264, 375-382	biotics and the dissem	ination of resistance genes,'	
EXAMINER		DATE CONSIDER	RED	



εĘ

#### COPY OF PAPERS ORIGINALLY FILED

Sheet 2 of 7

	_\_			Sheet 2 of 7	
	Form	PTO-1449 Modified	Docket No. PANT-0301	Serial No. 10/083,259	
	(	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Peter E. Nielsen, et al.		
		epartment of Commerce t and Trademark Office	Filing Date October 19, 2001	Group Not yet assigned	
	OTHE	R DOCUMENTS (Including Autho	or, Title, Date, Perti	nent Pages, Etc.)	
	AM	Demidov, et al., "Stability of peptide extracts," P.E. Biochem. Pharmacol	de nucleic acids in human serum and cellular		
	AN	Egholm, M., et al., "PNA hybridizes watson-crick hydrogen-bonding rule	s to complementary os," Nature, 1993, 3	oligonucleotides obeying the 65, 566-568	
	AO	Frimodt-Møller, N., et al., "The models of Infection, Chap. 14, 1999	ne mouse peritonitis/sepsis model," Handbook of Animal		
*	AP	Genbank, National Centre for Biote	chnology Informatio	n, USA	
	AQ Giwercman, B., et al., "Rapid emergence of resistance in <i>Pseudomonas au</i> cystic fibrosis patients due to in-vivo selection of stable partially derepres lactamase producing strains," <i>J. Antimicrob Chemother</i> , <b>1990</b> , 26, 247-25			partially derepressed β-	
AR Good, Liam, et al., "Antisense inhibition of gene expanded to mRNA," Nature Biotechnology, 1998, 16			nition of gene express nology, 1998, 16, 35	ression in bacteria by PNA 355-358	
	AS	Good, Liam, et al., "Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA," <i>Proc. Natl. Acad. Sci USA</i> , <b>1998</b> ,95, 2073-2076			
AT Gopher, A., et al., "Determination of fructose metabolic pathways in n fructose-intolerant children: a <sup>13</sup> C NMR study using [U- <sup>13</sup> C]fructose," <i>Acad. Sci. USA</i> , <b>1990</b> , <i>87</i> , 5449-5453			pathways in normal and <sup>13</sup> C]fructose," <i>Proc. Natl.</i>		
	AU Hanvey, J.C., et al., "Antisense and antigene properties of peptide nucleic Science, 1992, 258, 1481-1485				
	AV	Hiramatsu, K., et al., "Dissemination staphylococcus <i>aureus</i> heterogeneou 1670-1673	mination in Japanese hospitals of strains of rogeneously resistant to vancomycin," Lancet, 1997, 350,		
*	AW	House of Lords Select Committed on Science and Technology. Resistance to antibiotics and other antimicrobial agents. London, HMSO, 1998			
EXAM	INER		DATE CONSID	DERED	

<sup>\*</sup> A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



## COPY OF PAPERS ORIGINALLY FILED

Sheet 3 of 7

BI Fare Tri	ije) ·		Sheet 3 of 7	
	PTO-1449 Modified	Docket No. PANT-0301	Serial No. 10/083,259	
(	Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Peter E. Nielsen, et al.		
	epartment of Commerce t and Trademark Office	Filing Date October 19, 2001	Group Not yet assigned	
ОТНЕ	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
AX	Hsueh, P., et al., "Persistence of a mu in an intensive care burn unit," J. Cli	nultidrug-resistant psuedomonas aeruginosa clone lin. Microbiol, 1998, 36(5), 1347-1351		
AY	Johnson, A.P., "Intermediate vancon major threat or a minor inconvenience	nycin resistance in <i>stap</i> e?," <i>J. Antimicrob Ch</i>	phylococcus aureus: a emother, <b>1998</b> , 42, 289-291	
AZ	Knudsen, H., et al., "Antisense prope Nucleic Acids Res., 1996, 24(5), 494		plex-forming PNAs,"	
ВА	Lepelletier, D., et al., "Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains, Clin. Infect. Dis., 1999, 3, 548-552			
ВВ	Lewis, J.G., et al., "A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1996</b> , <i>93</i> , 3176-3181			
ВС	Livermore, D., "Multiresistance and 'superbugs'," Commun. Dis. Public Health, 1998, 1(2), 74-78			
BD	Livermore, D.M., "Acquired carbap 673-676	enemases," J. Antimic	rob Chemother, <b>1997</b> , 39,	
ВЕ	Mcneeley, D.F., et al., "An investigation of vancomycin-resistant enterococcus faecium within the pediatric service of a large urban medical center," Pediatr Infect. Dis. J., 1998, 17, 184-188			
BF	Meyer, O., et al., "Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides," <i>J. Biol. Chem.</i> , <b>1998</b> , <i>273</i> ( <i>25</i> ), 15621-15627			
BG	BG Nielsen, P.E., et al., "Peptide nucleic acid (:PNA), a DNA mimic with a pseudopeptide backbone," <i>Chemical Society Reviews</i> , 1997, 73-78			
ВН	Nielsen, P.E., et al., "Sequence-sele with a thymine-substituted polyamic	vtive recognition of DI de," Science, 1991, 254	NA by strand displacement 4, 1497-1500	
EXAMINER		DATE CONSIDER	RED	
1				

<sup>\*</sup> A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



### COPY OF PAPERS ORIGINALLY FILED

Sheet 4 of 7

1	William .	<i>]</i> ·		Sheet 4 of 7	
	Form	PTO-1449 Modified	Docket No. PANT-0301	Serial No. 10/083,259	
	(	Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Peter E. Nielsen, et al.		
		Department of Commerce t and Trademark Office	Filing Date October 19, 2001	Group Not yet assigned	
	ОТНЕ	R DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
	ВІ	Northey, D., et al., "Microbial surveing Gynaecol Obstet., 1974, 140(3), 321	illance in a surgical int -325	ensive care unit," Surg.	
	BJ	Nyce, J.W., et al., "DNA antisense the 1997, 385, 721-725	therapy for asthma in an animal model," Nature,		
	BK	Pooga, M., et al., "Cell penetrating F and modify pain transmission in vivo	PNA constructs regulato," Nature Biotechnolo	e galanin receptor levels egy, <b>1998</b> , <i>16</i> , 857-861	
	BL	Porter, E.A., et al., "Non-haemolytic 565	β-amino-acid oligome	ers," Nature, <b>2000</b> , 404,	
*	ВМ	Remington: The Science and practic	ce of Pharmacy, 19 <sup>th</sup> Ec	1., 1995	
	BN	BN Richards, M.J., et al., "Nosocomial infections in medical intensive care u United States," Crt Care Med., 1999, 27(5), 887-892			
	ВО	Vincent, J., et al., "The prevalence of Europe," <i>JAMA</i> , <b>1995</b> , <i>274(8)</i> , 639-6	of nosocomial infection 644	in intensive care units in	
	BP	Zervos, M., "Vancomycin-resistant quinupristin/dalfopristin," New Hor	enterococcus faecium i izons, 1996, 4(3), 385-	nfections in the ICU and 392	
	BQ	Chandrasekar, P.H., Nosocomial in intensive care units at a city hospital	fection among patients l, Critical Care Medici	in different types of ne, 1986, 14(15), 508-510	
	BR	Dowell, S.F., et al., "The best treatm 22, <b>1999</b> , <i>159</i> , 2511-2512	nent of pneumonia," An	ch Intern. Med., November	
	BS	Elliott, T.S.J., et al., "Infections and intravascular devices," <i>British J. Hosp</i> 1992, 48(8), 496-503			
	ВТ	Levy, S.B., "Microbial resistance to <i>The Lancet</i> , July 10, <b>1982</b> , 83-88	antibiotics: An evolvi	ng and persistent problem,"	
	BU	Liu, C.C., et al., "Investigation and staphylococcus aureus in a neonatal Journal Article, July/August 1993,	l intensive care unit," 7	Taiwan, Province of China,	
EXA	MINER	<u> </u>	DATE CONSIDE	RED	
L			10 D 1 1 1 1 1	and Office since it is	

<sup>\*</sup> A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



, yo

એ

:35 24

#### COPY OF PAPERS ORIGINALLY FILED

Sheet 5 of 7

Form	PTO-1449 Modified	Docket No. PANT-0301	Serial No. 10/083,259	
(	Patent and Publications Cited by Applicant veral sheets if necessary)	Applicant Peter E. Nielsen, et al.		
	epartment of Commerce t and Trademark Office	Filing Date October 19, 2001	Group Not yet assigned	
ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
BV	BV Egholm, M., et al., "Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA," <i>Nucleic Acids Res.</i> , 1995, 23(2), 217-222			
BW	Dufourcq, J. et al., "Molecular assembling of DNA with amphipathic peptides", FEBS LETT., 1998, Vol. 421, No. 1, pp. 7-11			
BX	BX Ishihara, T. et al., "Rules for Strand Invasion by Chemically Modified Oligonucleotides", J. Am. Chem. Soc., 1999, Vol. 121, No. 10, pp. 2012-2020			
BY Simmons, C. G. et al., "Synthesis and membrane permeability of pna-peptide conjugates", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , <b>December 2, 1997</b> , Vol. No. 23, pp. 3001-3006				
EXAMINER		DATE CONSIDER	ED	



### COPY OF PAPERS ORIGINALLY FILED

Sheet 6 of 7

	TAN-		····			Sheet 6 of /	
	Form PTO-1449 Modified			Docket No. Serial No. 10/083,259			
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office			Applicant Peter E. Nielsen, et al.				
			Filing Date October 19, 2001	Group Not yet assigned			
		U. S	. PATENT D	OCUMENTS		•	
Examiner Document No. Date				Name	Class	Subclass	
	BZ	5,652,211	07/29/97	April 4, 2002	514	11	
	CA	5,777,078	07/07/98	Bayley, et al.	530	350	
	СВ	5,834,430	11/10/98	Porro, et al.	514	14	
		FORE	IGN PATENT	DOCUMENTS			
Examiner Initial		Document No.	Date	Country	YES Tr	Translation YES NO	
	CC	WO 92/20702	11/26/92	PCT			
	CD	WO 92/20703	11/26/92	PCT			
	CE	WO 96/02558	02/01/96	PCT			
	CF	WO 96/38163	12/05/96	PCT			
	CG	WO 96/11205	04/18/96	PCT			
	СН	WO 98/03533	01/29/98	PCT			
	CI	WO 98/32467	07/30/98	PCT			
	CJ	WO 98/52614	11/26/98	PCT			
	CK	WO 99/05302	02/04/99	PCT			
	CL	WO 99/13893	03/25/99	PCT			
	CM	WO 99/14226	03/25/99	PCT			
	CN	PA 1999 01734	12/03/99	Denmark			
	СО	PA 1999 01735	12/03/99	Denmark			
EXAMINER			DATE CONSIDER	RED			



# COPY OF PAPERS ORIGINALLY FILED

Sheet 7 of 7

Form PTO-1449 Modified				Docket No. PANT-0301	Serial No. 10/083,259	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Applicant Peter E. Nielsen, et al.		
U.S. Department of Commerce Patent and Trademark Office				Filing Date October 19, 2001	Group Not yet as	signed
		U. S	. PATENT DO	CUMENTS		
Examiner Document No. Date			Name	Class	Subclass	
				<u> </u>		
	,	FORE	IGN PATENT	DOCUMENTS	1	
Examiner Initial	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Country	YES Tra	nslation NO	
	СР	PA 1999 01467	10/13/99	Denmark		
	CQ	PA 1999 01471	10/13/99	Denmark		
	CR	PA 2000 00522	03/28/00	Denmark		
	CS	PA 2000 00670	04/19/00	Denmark		
	CT	PA 2000 00671	04/19/00	Denmark		
EXAMINE	EXAMINER			DATE CONSIDE	RED	